HUP0204515A2 - 4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0204515A2 HUP0204515A2 HU0204515A HUP0204515A HUP0204515A2 HU P0204515 A2 HUP0204515 A2 HU P0204515A2 HU 0204515 A HU0204515 A HU 0204515A HU P0204515 A HUP0204515 A HU P0204515A HU P0204515 A2 HUP0204515 A2 HU P0204515A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkenyl
- alkyl
- optionally substituted
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical class NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 101150039148 NHX1 gene Proteins 0.000 abstract 1
- 201000005746 Pituitary adenoma Diseases 0.000 abstract 1
- 206010061538 Pituitary tumour benign Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 208000021310 pituitary gland adenoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek, racém, enantiomerformában, vagy ezek bármilyen kombinációjában, ahol a képletben R1jelentése lineáris vagy elágazó láncú 1-16 szénatomos alkil-,alkenil-, alkinil-, -(CH2)m-Y-Z11 vagy -(CH2)m-Z12 csoport, R2jelentése -C(Y)NHX1, -C(O)X2 vagy SO2X3 képletű csoport; R3 jelentésehidrogénatom, adott esetben szubsztituált alkil-, alkenil-, alkinil-,aralkilcsoport, adott esetben szubsztituált heteroarilalkilcsoportvagy -C(Y)-NHX11, -(CH2)n-C(O)X2, SO2X3 képletű csoport; X1 jelentéselineáris vagy elágazó láncú 1-15 szénatomos alkil-, alkenil-,alkinil-, -(CH2)m-Y-Z21, vagy -C(H2)pZ22 képletű csoport, X2 jelentéselineáris vagy elágazó láncú 1-10 szénatomos alkilcsoport,alkenilcsoport, amely adott esetben fenilcsoporttal van helyettesítve,ahol a fenilcsoport adott esetben önmagában is helyettesített lehet,alkinilcsoport vagy -(CH2)m,-W-(CH2)q-Z23 vagy -(CH2)p-U-Z24 képletűcsoport, X3 jelentése lineáris vagy elágazó láncú 1-10 szénatomosalkilcsoport, alkenilcsoport, amely adott esetben fenilcsoporttal vanhelyettesítve, ahol a fenilcsoport adott esetben önmagában ishelyettesített lehet, CF3 vagy -(CH2)pZ25 képletű csoport, Y jelentéseoxigénatom vagy kénatom; W jelentése oxigénatom vagy kénatom vagy SO2csoport; U jelentése kovalens kötés vagy oxigénatom; n értéke 0-4 egészszám; m értéke 1-6 egész szám; p jelentése 0-6 egész szám; q jelentése0-2 egész szám; vagy ezek gyógyászatilag elfogadható ásványi vagyszerves savakkal alkotott savaddíciós sói, azzal a megkötéssel, hogyaz (I) általános képletű vegyületekben R1 jelentése alkilcsoporttól,alkenilcsoporttól vagy benzilcsoporttól különböző; R2 csoportjelentése adott esetben szubsztituált benziloxicsoporttól különböző ésR3 jelentése aralkilcsoporttól különböző. A találmány tárgyát képezimég az (1) általános képletű vegyületek gyógyászati alkalmazása,elsősorban acromegalia, hipofízises adenoma vagy daganatok kezelésére. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9915724A FR2802206B1 (fr) | 1999-12-14 | 1999-12-14 | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
PCT/FR2000/003497 WO2001044191A1 (fr) | 1999-12-14 | 2000-12-13 | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0204515A2 true HUP0204515A2 (hu) | 2003-04-28 |
HUP0204515A3 HUP0204515A3 (en) | 2005-04-28 |
HU227838B1 HU227838B1 (en) | 2012-05-02 |
Family
ID=9553215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0204515A HU227838B1 (en) | 1999-12-14 | 2000-12-13 | 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
Country Status (23)
Country | Link |
---|---|
US (4) | US7115634B2 (hu) |
EP (1) | EP1286966B1 (hu) |
JP (2) | JP4838474B2 (hu) |
KR (2) | KR20070014235A (hu) |
CN (1) | CN1207283C (hu) |
AR (1) | AR034244A1 (hu) |
AT (1) | ATE401308T1 (hu) |
AU (1) | AU779341B2 (hu) |
CA (1) | CA2394086C (hu) |
CY (1) | CY1108415T1 (hu) |
CZ (1) | CZ305360B6 (hu) |
DE (1) | DE60039539D1 (hu) |
DK (1) | DK1286966T3 (hu) |
ES (1) | ES2310529T3 (hu) |
FR (1) | FR2802206B1 (hu) |
HK (1) | HK1054029A1 (hu) |
HU (1) | HU227838B1 (hu) |
MY (1) | MY126973A (hu) |
NZ (1) | NZ520071A (hu) |
PL (1) | PL204864B1 (hu) |
PT (1) | PT1286966E (hu) |
RU (1) | RU2266282C2 (hu) |
WO (1) | WO2001044191A1 (hu) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
EP1311502A1 (en) * | 2000-08-17 | 2003-05-21 | Celltech R&D Limited | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
MXPA04001016A (es) * | 2001-08-03 | 2004-05-27 | Schering Corp | Derivados de sulfonamida como inhibidores de la gamma secretasa. |
US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
ES2349118T3 (es) * | 2001-09-14 | 2010-12-28 | High Point Pharmaceuticals, Llc | Nuevos derivados de aminoazetidina, pirrolidina y piperidina. |
JP4619655B2 (ja) | 2001-09-14 | 2011-01-26 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体 |
CN100462359C (zh) * | 2001-11-28 | 2009-02-18 | 科学研究和应用咨询公司 | 5-硫烷基-4h-1,2,4-三唑衍生物及其作为药物的应用 |
FR2832710B1 (fr) * | 2001-11-28 | 2004-09-03 | Sod Conseils Rech Applic | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments |
KR20100008799A (ko) | 2001-12-28 | 2010-01-26 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
DE60316116T2 (de) * | 2002-02-01 | 2008-05-29 | Novo Nordisk A/S | Amide von aminoalkylsubstituierten azetidinen, pyrrolidinen, piperidinen und azepanen |
US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
AU2003247615B2 (en) * | 2002-06-24 | 2007-08-09 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
TW200409637A (en) | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
WO2004009549A2 (en) * | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
CA2512639C (en) | 2003-01-16 | 2012-10-30 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
GB0314054D0 (en) * | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
WO2004110995A1 (en) * | 2003-06-17 | 2004-12-23 | Pfizer Limited | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
JP2008505100A (ja) * | 2004-06-30 | 2008-02-21 | シェーリング コーポレイション | ガンマ−セクレターゼ阻害剤としての置換n−アリールスルホニル複素環アミン |
EP2289879B1 (en) | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
PT1893603E (pt) * | 2005-06-02 | 2009-11-24 | Hoffmann La Roche | Derivados de piperidin-4-il-amida e a sua utilização como antagonistas do receptor de sst do subtipo 5 |
ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
ATE538116T1 (de) | 2006-05-29 | 2012-01-15 | High Point Pharmaceuticals Llc | 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist |
US7674804B2 (en) | 2006-06-29 | 2010-03-09 | Hoffmann-La Roche Inc. | Pyrimidine and quinazoline derivatives as SST5 modulators |
WO2008116024A2 (en) | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
EP2014656A3 (en) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
JP2010540454A (ja) * | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ,インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
EP2060564A1 (en) * | 2007-11-19 | 2009-05-20 | Ludwig-Maximilians-Universität München | Non-peptidic promoters of apoptosis |
CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
ES2352398B1 (es) * | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciencia I Tecnologia S.A. | N-fenetilsulfonamidas-n-sustituidas para la identificacion de actividad biologica y farmacologica. |
ES2727481T3 (es) * | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
JP6317675B2 (ja) | 2011-11-30 | 2018-04-25 | サレプタ セラピューティクス, インコーポレイテッド | 延長リピート病を処置するためのオリゴヌクレオチド |
WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
AU2014255381A1 (en) * | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
PL3053916T3 (pl) | 2013-09-30 | 2019-06-28 | Ono Pharmaceutical Co., Ltd. | Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanie |
KR101541647B1 (ko) | 2014-04-24 | 2015-08-03 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
PL3325444T3 (pl) | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
CA2996164A1 (en) | 2015-08-28 | 2017-03-09 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
EP3349743B1 (en) | 2015-09-18 | 2022-04-06 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
KR20210134838A (ko) | 2016-07-14 | 2021-11-10 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 그의 용도 |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
BR112019019168A2 (pt) | 2017-03-16 | 2020-04-14 | Crinetics Pharmaceuticals Inc | moduladores de somatostatina e usos dos mesmos |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
KR20200043409A (ko) | 2017-08-21 | 2020-04-27 | 아카디아 파마슈티칼스 인코포레이티드 | 질병 치료를 위한 화합물, 이의 염 및 방법 |
EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
KR102462586B1 (ko) | 2018-01-17 | 2022-11-03 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제의 제조 방법 |
WO2019157458A1 (en) | 2018-02-12 | 2019-08-15 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
JP7431813B2 (ja) | 2018-09-18 | 2024-02-15 | クリネティックス ファーマシューティカルズ,インク. | ソマトスタチンモジュレーターとその使用 |
WO2021030262A1 (en) | 2019-08-14 | 2021-02-18 | Crinetics Pharmaceuticals, Inc. | Nonpeptide somatostatin type 5 receptor agonists and uses thereof |
US11655235B2 (en) | 2019-11-06 | 2023-05-23 | Yuhan Corporation | Pyrrolidine and piperidine compounds |
EP4186893A1 (en) * | 2020-07-22 | 2023-05-31 | Geneora Pharma (Shijiazhuang) Co., Ltd. | 5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof |
EP4210700A1 (en) | 2020-09-09 | 2023-07-19 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
MX2023009603A (es) | 2021-02-17 | 2023-08-24 | Crinetics Pharmaceuticals Inc | Formas cristalinas de un modulador de somatostatina. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1425354A (en) * | 1973-10-10 | 1976-02-18 | Wyeth John & Brother Ltd | Indole derivatives |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPS5152176A (hu) * | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
JPS5285174A (en) * | 1976-01-05 | 1977-07-15 | Yoshitomi Pharmaceut Ind Ltd | Novel urea or thiourea derivatives |
GB1574418A (en) * | 1976-11-16 | 1980-09-03 | Anphar Sa | Piperidine derivatives |
US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
AU1285499A (en) * | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
JP2002501898A (ja) * | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
CN1356977A (zh) * | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
IL151164A0 (en) * | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
-
1999
- 1999-12-14 FR FR9915724A patent/FR2802206B1/fr not_active Expired - Lifetime
-
2000
- 2000-12-13 PT PT00993405T patent/PT1286966E/pt unknown
- 2000-12-13 AT AT00993405T patent/ATE401308T1/de active
- 2000-12-13 DK DK00993405T patent/DK1286966T3/da active
- 2000-12-13 HU HU0204515A patent/HU227838B1/hu unknown
- 2000-12-13 ES ES00993405T patent/ES2310529T3/es not_active Expired - Lifetime
- 2000-12-13 RU RU2002118705/04A patent/RU2266282C2/ru active
- 2000-12-13 KR KR1020077001118A patent/KR20070014235A/ko not_active Application Discontinuation
- 2000-12-13 CZ CZ2002-2060A patent/CZ305360B6/cs not_active IP Right Cessation
- 2000-12-13 CA CA2394086A patent/CA2394086C/fr not_active Expired - Lifetime
- 2000-12-13 DE DE60039539T patent/DE60039539D1/de not_active Expired - Lifetime
- 2000-12-13 JP JP2001544681A patent/JP4838474B2/ja not_active Expired - Lifetime
- 2000-12-13 EP EP00993405A patent/EP1286966B1/fr not_active Expired - Lifetime
- 2000-12-13 CN CNB008171777A patent/CN1207283C/zh not_active Expired - Lifetime
- 2000-12-13 WO PCT/FR2000/003497 patent/WO2001044191A1/fr active IP Right Grant
- 2000-12-13 NZ NZ520071A patent/NZ520071A/xx not_active IP Right Cessation
- 2000-12-13 US US10/130,924 patent/US7115634B2/en not_active Expired - Lifetime
- 2000-12-13 KR KR1020027007506A patent/KR100725190B1/ko active IP Right Grant
- 2000-12-13 MY MYPI20005862A patent/MY126973A/en unknown
- 2000-12-13 AU AU28560/01A patent/AU779341B2/en not_active Expired
- 2000-12-13 PL PL356365A patent/PL204864B1/pl unknown
- 2000-12-14 AR ARP000106648A patent/AR034244A1/es active IP Right Grant
-
2003
- 2003-09-03 HK HK03106281.2A patent/HK1054029A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 US US11/122,293 patent/US7393861B2/en not_active Expired - Lifetime
-
2008
- 2008-05-02 US US12/151,115 patent/US7858789B2/en not_active Expired - Fee Related
- 2008-10-14 CY CY20081101138T patent/CY1108415T1/el unknown
-
2010
- 2010-11-15 US US12/946,504 patent/US8110574B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 JP JP2011024405A patent/JP2011121982A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0204515A2 (hu) | 4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0401837A2 (hu) | Dikarbonsavszármazékok, előállításuk és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
PE58699A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
TW200635585A (en) | Monocyclic substituted methanones | |
JP2002155281A5 (hu) | ||
ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
RS87204A (en) | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | |
RU2008136769A (ru) | Аминоацильные производные пролекарства и лекарственные средства для лечения тромбоэмболических заболеваний | |
HUP0202414A2 (hu) | Új eljárás perindopril és analógjai, és ezek sói előállítására | |
MXPA03000547A (es) | Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares. | |
HUP0203471A2 (hu) | Trombózisellenes hatású vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE104292T1 (de) | Verbindungen fuer die induktion der in vitround in vivo-erzeugung von cytokinen. | |
HU0104272D0 (en) | New cyclobutendione compounds a process for their preparation and pharmaceutical compositions containing them | |
DK0732332T3 (da) | Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf | |
RU2010104475A (ru) | Аминоацильные пролекарства в качестве фармацевтически действующих веществ для лечения тромбоэмболических заболеваний | |
ATE116647T1 (de) | Thiophenderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
TW273553B (hu) | ||
HUP0203383A2 (hu) | Aminofenoxiacetamid-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0102447A2 (hu) | Új oktahidro-6,10-dioxo-6H-piridazino[1,2-a][1,2]diazepin-1-karbonsav-származékok, eljárás a vegyületek előállítására és alkalmazásuk gyógyászati hatóanyagok előállítására | |
HUP0103113A2 (hu) | NOS inhibitorokat tartalmazó gyógyászati készítmények | |
SE9901884D0 (sv) | Novel compounds their use and preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: IPSEN PHARMA S.A.S., FR Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.), FR |